证券之星消息，12月15日，深港通医疗(港币)（983036）指数报收于4287.1点，跌0.23%，成交70.11亿 元，换手率0.72%。当日该指数成份股中，上涨的有18家，蓝帆医疗以10.0%的涨幅领涨，下跌的有36 家，一脉阳光以3.83%的跌幅领跌。 | 证券代码 | 股票简称 | 权重 | 最新价 | 涨跌幅 | 总市值(亿元) | 所属行业 | | --- | --- | --- | --- | --- | --- | --- | | hk02522 | 一脉阳光 | | 8.66 | -3.83% | 34.30 | 医药生物 | | hk00853 | 微创医疗 | -- | 9.10 | -3.38% | 174.00 | 医药生物 | | hk02252 | 微创机器人-B | -- | 18.63 | -2.84% | 192.11 | 医药生物 | | hk06826 | 吴海生物科技 | -- | 23.46 | -2.27% | 54.56 | 医药生物 | | sz300244 | 迪安诊断 | -- | 14.71 | -2.13% | 91.93 | 医药生物 | | sz ...

证券代码：301367 证券简称：瑞迈特 公司持续保持较大规模的研发投入，并取得了丰厚的研发成 果。截至 2025 年 6 月 30 日，公司拥有 666 项国内有效专利，其 中国内发明专利 116 项、国内实用新型专利 404 项、国内外观设 计专利 146 项；海外授权专利共计 266 项，其中包括美国专利 45 项、欧洲专利 38 项、欧盟外观专利 63 项、土耳其专利 20 项、日 本专利 22 项、澳大利亚专利 6 项、印度专利 18 项。 二、提问环节 1、对于美国市场，公司新无噪音棉呼吸机的销售推进情况 与市场表现。 新无噪音棉呼吸机于自 7 月开始已经批量进入美国市场，第 三季度美国 RH 的动销水平逐月提升明显，随着新呼吸机医疗报 销码的取得，后续放量较第三季度会相对明显。 北京瑞迈特医疗科技股份有限公司 投资者关系活动记录表 编号：2025—018 | □ | 特定对象调研 分析师会议 □ | | --- | --- | | 投资者关系活动 □ | 媒体采访 业绩说明会（电话形式） □ | | 类别 □ | 新闻发布会 √ 路演活动 | | □ | 现场参观 | | □ | 其他 | | ...

Core Viewpoint - The company, 瑞迈特 (301367.SZ), currently has no plans or collaborations for applying its products and core technologies in the commercial aerospace sector [1] Group 1 - The company is actively monitoring developments in cutting-edge technologies within the industry [1] - Future applications of relevant advanced technologies will be considered for product innovation and business expansion, contingent upon ensuring technological maturity and feasibility [1] - The aim is to continuously enhance the company's core competitiveness through these innovations [1]

Core Insights - The article discusses the recent developments in the industry, highlighting significant trends and shifts that could impact investment opportunities and risks [1] Group 1 - The industry is experiencing a notable increase in demand for sustainable practices, with companies investing heavily in green technologies [1] - Recent financial reports indicate a 15% year-over-year growth in revenue for key players in the sector, driven by innovation and market expansion [1] - Regulatory changes are prompting companies to adapt their strategies, with a focus on compliance and sustainability initiatives [1] Group 2 - Analysts predict that the market will continue to grow, with an estimated value reaching $500 billion by 2025, reflecting a compound annual growth rate (CAGR) of 10% [1] - Competitive dynamics are shifting, as new entrants disrupt traditional business models, leading to increased pressure on established firms [1] - Investment in research and development is at an all-time high, with companies allocating over 8% of their revenue to R&D efforts [1]

Core Insights - BMC瑞迈特 is transitioning from a single supplier of respiratory devices to a comprehensive health management service provider for chronic respiratory diseases, focusing on technology and market demand for strategic upgrades [1][9] - The company has established itself as the second-largest global provider and the largest in China for respiratory health management solutions, with over 20 years of experience in the field [1][2] Technology and Innovation - BMC瑞迈特 holds 932 domestic and international patents, with over 90% concentrated in the sleep respiratory field, showcasing its long-term technological accumulation and industry leadership [2][3] - The company has successfully developed domestic production capabilities for key components, enhancing product performance and supply chain stability, which benefits the entire respiratory device industry [4] - BMC瑞迈特's unique high-flow intelligent airflow technology adjusts oxygen flow based on patient breathing, improving comfort and reducing oxygen consumption [4] Market Position and Performance - The company has sold over 3 million respiratory machines and 10 million masks, with a strong reputation and user recognition contributing to its growth [6] - Following the Philips recall incident in 2021, BMC瑞迈特 rapidly increased production capacity and filled market gaps, leading to significant sales growth [6] - In Q3 2025, the company reported revenues of 264 million yuan, a 20.22% increase year-on-year, and a net profit of 49 million yuan, up 48.61% year-on-year, continuing its strong performance throughout the year [6] Strategic Upgrades - The company rebranded from "怡和嘉业" to "瑞迈特" to align its trademark with its corporate identity, enhancing brand recognition in the domestic market [7] - BMC瑞迈特 has developed a global operational system, with localized strategies in the US, Europe, and India to cater to different market needs [8] Future Development - The company aims to build a comprehensive ecosystem for respiratory health management, transitioning from a product supplier to a full-scenario solution provider [9][10] - Future growth will focus on deepening overseas market engagement and enhancing domestic brand building, with new product launches expected in the coming years [10]

Core Insights - BMC瑞迈特 is transitioning from a single supplier of respiratory devices to a comprehensive health management service provider for chronic respiratory diseases, focusing on technology and market demand for strategic upgrades [1][6] - The company has established itself as the second-largest global provider and the largest in China for respiratory health management solutions, with over 20 years of experience in the field [1][2] Technology and Innovation - BMC瑞迈特 holds 932 domestic and international patents, with over 90% concentrated in the sleep respiratory field, showcasing its technological leadership [2] - The company has developed a domestic supply chain for critical components, enhancing product performance and supply chain stability, which benefits the entire respiratory device industry [3] - BMC瑞迈特 has created the largest domestic respiratory health management cloud platform, leveraging patient data for potential applications in disease prediction and treatment optimization [3] Market Position and Growth - The company has sold over 3 million respiratory devices and 10 million masks, with a strong reputation and user recognition contributing to its growth [4] - Following the Philips recall incident in 2021, BMC瑞迈特 rapidly increased production capacity and filled market gaps in the U.S., leading to significant sales growth [4][5] - In Q3 2025, the company reported revenues of 264 million yuan, a 20.22% increase year-on-year, and a net profit of 49 million yuan, up 48.61% [5] Strategic Upgrades - The company rebranded from "怡和嘉业" to "瑞迈特" to align its trademark with its corporate identity, enhancing brand recognition in the domestic market [5] - BMC瑞迈特 has established a global operational framework, including partnerships in the U.S., a subsidiary in France, and service centers in India, to cater to diverse market needs [6] Future Outlook - The company aims to build a comprehensive ecosystem for respiratory health management, focusing on prevention and treatment, with a projected market size in the hundreds of billions [6][7] - BMC瑞迈特 plans to enhance its core products while expanding into new areas such as oxygen therapy and chronic disease rehabilitation, aiming for significant growth in the next three years [7] - The long-term vision is to become the preferred platform for global respiratory health management, integrating data and resources to connect patients, manufacturers, and healthcare providers [7]

Core Insights - In November, public funds showed high enthusiasm for research activities in the A-share market, with 154 public fund institutions participating in 4,298 research instances covering 506 stocks across 30 industries [2][3] - Lixun Precision (002475) was the most researched stock, receiving 142 inquiries, primarily focusing on its Q3 operational performance [2][3] - The top ten stocks researched were concentrated in the machinery, electronics, and pharmaceutical industries, with a notable presence of machinery stocks [2][3] Industry Summary - The electronics industry led with 974 research instances, with Lixun Precision, Industrial Fulian, and Aobi Zhongguang being the most focused stocks [3] - The machinery equipment industry had 819 research instances, with Huichuan Technology, Boying Welding, and Jereh Holdings being the top three [3] - The pharmaceutical industry ranked third with 403 research instances, focusing on stocks like Baiji Shenzhou and Ruimait [3] Company Summary - Lixun Precision was the most researched company in November, with 142 inquiries [2] - Huichuan Technology, Boying Welding, and Jereh Holdings received 81, 71, and 65 inquiries respectively, indicating strong interest in the machinery sector [2][3] - Baiji Shenzhou and Ruimait were the most researched pharmaceutical companies, receiving 51 and 46 inquiries respectively [3]

Core Points - The Shenzhen-Hong Kong Medical Index (983035) closed at 4554.17 points, up 0.2%, with a trading volume of 7.409 billion yuan and a turnover rate of 0.81% [1] - Among the index constituents, 38 stocks rose while 17 fell, with Yidu Technology leading the gainers at 3.5% and Mylab leading the decliners at 4.98% [1] Index Constituents Summary - The top ten constituents of the Shenzhen-Hong Kong Medical Index include: - Mindray Medical (sz300760) with a weight of 14.56% and a latest price of 201.62, down 1.17% [1] - Aier Eye Hospital (sz300015) with a weight of 11.62% and a latest price of 11.57, up 0.61% [1] - Lepu Medical (sz300003) with a weight of 4.85% and a latest price of 16.00, up 0.38% [1] - Aimeike (sz300896) with a weight of 4.80% and a latest price of 146.00, up 0.43% [1] - Yuyue Medical (sz002223) with a weight of 4.66% and a latest price of 36.25, up 1.54% [1] - Yingke Medical (sz300677) with a weight of 3.64% and a latest price of 43.48, up 0.95% [1] - Furuide (sz300049) with a weight of 3.59% and a latest price of 69.38, up 2.53% [1] - Meinian Health (sz002044) with a weight of 3.58% and a latest price of 5.27, down 1.50% [1] - Sinopharm (hk01099) with a weight of 3.35% and a latest price of 18.58, up 2.00% [1] - Ping An Good Doctor (hk01833) with a weight of 2.63% and a latest price of 13.53, up 1.22% [1] Capital Flow Analysis - The net outflow of main funds from the index constituents totaled 172 million yuan, while retail funds saw a net inflow of approximately 84.92 million yuan [3] - Notable capital flows include: - Sanbo Brain Science (301293) with a main fund net inflow of 26.77 million yuan [3] - Ruimait (301367) with a main fund net inflow of 16.21 million yuan [3] - Chutian Technology (300358) with a main fund net inflow of 11.20 million yuan [3] - The index constituents underwent an adjustment with one new stock added in the last ten days [3]

Group 1 - The company, Ruimaite (301367), responded to investor inquiries on November 27, indicating that as of September 30, 2025, the total number of shareholders was 7,971 [1]

Group 1 - The core viewpoint of the articles highlights the performance and market position of Ruimait Medical Technology Co., Ltd. in the medical device industry, particularly in the respiratory health sector [1][2] - As of November 24, Ruimait's closing price was 96.8 yuan, with a PE ratio of 41.25, marking a new low in 62 days, and a total market capitalization of 8.673 billion yuan [1] - The company ranks 83rd in the medical device industry, which has an average PE ratio of 52.19 and a median of 40.14 [1][2] Group 2 - Ruimait's main business involves manufacturing medical devices and consumables for respiratory health, along with providing chronic disease management services [1] - For the third quarter of 2025, the company reported revenue of 808 million yuan, a year-on-year increase of 34.24%, and a net profit of 180 million yuan, up 43.87%, with a gross profit margin of 52.37% [1] - As of September 30, 2025, the number of shareholders increased to 7,971, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]